The Beauty Health Company (SKIN) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals positive developments: increased revenue and EBITDA guidance, successful price hikes, and promising product launches. Although device sales face challenges, consumables show growth, and stabilization efforts are underway. The company's focus on innovation and strategic pricing, coupled with a positive market response to price increases, indicates a potential stock price uplift. However, management's lack of specific guidance for 2026 and ongoing macroeconomic pressures temper expectations, suggesting a moderate positive sentiment.
Key Financial Performance
Total Net Sales $70.7 million, down 10.3% year-over-year, primarily due to continued pressure on equipment sales globally and the impact of the China transition to a distributor partner.
Device Segment Revenue $20.8 million, a decrease of 24.6% year-over-year, primarily reflecting continued pressure on equipment sales globally and the impact of the China transition to a distributor partner.
Consumables Segment Revenue $49.8 million, a decrease of 2.6% year-over-year, primarily reflecting the change in the China business model. Excluding the China impact, consumables sales would have increased modestly versus last year.
Consumable Mix Increased from 65% of net sales in Q3 of last year to 71% this quarter, driven by the shift in the China business model.
Adjusted Gross Margins 68%, a decline of approximately 150 bps from Q3 of last year, driven primarily by lower average selling prices as distributor markets held a larger unit share of the overall equipment revenue year-over-year.
Adjusted EBITDA $8.9 million, up 11% from Q3 of last year, reflecting tight control of costs and solid operational execution.
Regional Revenue - Americas $48.3 million, a decline of 7% year-over-year, reflecting softer U.S. trends.
Regional Revenue - APAC $6.3 million, a decrease of 41.5% year-over-year, reflecting the planned go-to-market transition in China.
Regional Revenue - EMEA $16.1 million, relatively flat year-over-year.
Total Active Machines in the Field 35,409 units as of September 30, 2025, up from 34,162 units at the end of Q3 2024, reflecting global footprint expansion.
GAAP Gross Profit $45.6 million, an increase of 12.3% year-over-year, driven primarily by lower inventory write-offs and a mix shift towards high-margin consumables revenue.
Selling and Marketing Expenses $20.9 million, a decrease of 24.2% year-over-year, primarily due to lower headcount and targeted spending.
R&D Expenses $1.7 million, an increase of 53.2% year-over-year, primarily driven by higher professional service expenses related to early-stage future product investments.
G&A Expenses $29.3 million, a decrease of 12.5% year-over-year, driven by lower headcount and bad debt recovery, partially offset by higher legal and incentive-related costs.
Operating Loss $6.2 million, a significant improvement versus a loss of $21.5 million in the comparable prior year.
Adjusted EBITDA Margin 12.6%, an improvement of approximately 240 basis points year-over-year, reflecting continued cost control despite lower top-line volume.
Inventory $56.1 million, down from $69.1 million at year-end, reflecting stronger demand planning and improved supply chain efficiency.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Hydrafacial device platform: Focus on expanding it into a category-leading ecosystem of skin health technology solutions.
Hydralock HA and HydraFillic with Pep9 Boosters: Contributed to 14% growth in the booster sales category this quarter.
Global network of providers: BeautyHealth is leveraging its global network to deliver treatments worldwide.
China market transition: Shifted from a direct seller to a distributor model, impacting device and consumable sales.
Inventory management: Inventory held below $60 million, the lowest in 3 years, due to improved demand planning and production quality.
Adjusted EBITDA: Increased to $8.9 million, up 11% from Q3 last year, reflecting tight cost control and operational execution.
Focus areas for growth: Prioritizing Hydrafacial installed base growth, consumable utilization, innovation in devices and consumables, and operational discipline.
Debt restructuring: Extended debt maturity profile and enhanced financial flexibility through convertible note exchange.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Device Sales Pressure: Device sales declined 24.6% year-over-year, reflecting global pressure on equipment sales and the impact of transitioning to a distributor model in China. This indicates challenges in maintaining device sales growth, which is critical for driving recurring consumable revenue.
China Business Model Transition: The shift from a direct seller to a distributor model in China led to lower device and consumable sales, impacting overall revenue. This transition poses risks related to market penetration and revenue consistency in a key region.
Macroeconomic Environment: Inflation, challenging access to financing for capital equipment purchases, and uneven consumer confidence, especially in discretionary categories, create a tough operating environment that could hinder sales and profitability.
Regional Revenue Declines: Revenue in the Americas declined by 7%, and APAC revenue decreased by 41.5%, driven by the China transition. These regional declines highlight vulnerabilities in geographic market performance.
Lower Average Selling Prices: Adjusted gross margins declined due to lower average selling prices, particularly as distributor markets held a larger share of equipment revenue. This could pressure profitability if the trend continues.
Operational Challenges: While operational discipline has improved, maintaining cost control, margin expansion, and supply chain efficiency remains critical to offset revenue pressures and ensure profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Adjusted EBITDA Guidance: The company is raising adjusted EBITDA guidance for the remainder of the year as well as the midpoint of full-year revenue guidance. Adjusted EBITDA guidance for the full year 2025 is increased to between $37 million and $39 million. For Q4, adjusted EBITDA is expected to be between $6.9 million and $8.9 million.
Revenue Guidance: The company is raising the low end of its full-year 2025 revenue guidance to between $293 million and $300 million. For Q4, net sales are expected to be between $74.5 million and $81.5 million.
Market Trends and Strategic Focus: The company plans to focus on expanding its Hydrafacial device footprint, increasing consumable utilization, and innovating across devices and consumable platforms. It aims to strengthen operational discipline in areas such as cost control, margin expansion, and supply chain management.
Future Product Innovation: The company will continue to bring to market superior clinically backed products to meet provider needs and deliver desired results for customers.
Macroeconomic Environment: The company acknowledges a tough and unpredictable environment with challenges such as inflation, financing access for capital equipment purchases, and uneven consumer confidence in discretionary categories. Despite this, it plans to focus on controllable levers to drive growth and profitability.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the trends in the Americas and EMEA regions, and how do they compare?
A:In the Americas, which accounts for 65% of total revenue, overall revenue was down 7%, with devices down 16.3% due to lower device placements and macroeconomic pressures. However, the decline in Q3 was less than in the previous two quarters, indicating stabilization. Consumables were down 2.7%, driven by lower device placements earlier in the year and consumer spending headwinds, though booster sales increased. In EMEA, which accounts for 25% of total sales, revenue was flat. Devices were down 21% due to lower consumer confidence and a crowded market, but consumables grew by 10%, driven by strong performance in Germany and the medical channel.
Q:What are the near-term and long-term focus areas for the company?
A:The company is focusing on driving utilization, device placement, and innovation in both devices and consumables. Near-term efforts include addressing providers' financing challenges, implementing targeted pricing strategies, and reinforcing commercial discipline. Long-term plans involve launching clinically backed products, improving post-sales onboarding, and driving consumer mindshare. The company has paused its skincare initiative to focus on its core business of clinical differentiation and recurring consumables.
Q:What is the company's international strategy regarding direct versus distributor models?
A:The company will continue leveraging its extensive distributor network to drive penetration and reach while investing in education and training to help distributors increase market penetration. The international strategy remains largely unchanged, focusing on targeted commercial programs tailored to regional economics.
Q:How has the market responded to the recent price increase on consumables?
A:The market has responded positively to the 5% price increase on consumables implemented in July. Average selling prices (ASP) for consumables have increased, driven by the price hike and higher booster sales.
Q:What initiatives are being implemented to stabilize and grow device sales?
A:The company is addressing providers' financing challenges, implementing targeted pricing strategies, and improving commercial discipline. The "good, better, best" program offers flexible price points, and the company is focusing on lead conversion and expanding its global device footprint. Despite a decline in device sales, the company sold 875 additional units in Q3 and expects stabilization and improvement as financing access and sales execution improve.
Q:What is the company's focus in the consumables segment?
A:The company is focusing on innovation by launching differentiated boosters with clinical proof, equipping providers with impactful marketing tools, and investing in education. It has paused its skincare initiative to concentrate on its core business of clinical differentiation and recurring consumables.
Q:What trends are being observed in different channels and among end consumers?
A:In the U.S., the medical segment (70% of providers) is facing challenges due to macroeconomic pressures, with med spas being the largest and growing segment. Plastic surgeons are experiencing a slowdown as consumers prioritize less invasive care. The non-medical segment, including day spas, is stable. Booster attachment rates are high, driven by innovation, but utilization rates for standard Hydrafacial treatments are under pressure. The company is focusing on education and training to address these challenges.
Q:What is the company's strategy for balancing top-line growth and profitability?
A:The company aims to drive top-line growth while maintaining profitability by leveraging its recurring revenue business model. It plans to focus on improving device momentum, commercial execution, and operating leverage to expand EBITDA. The company is cautious about macroeconomic pressures and consumer spending but is optimistic about its setup for the next year.
Q:What are the financial highlights and guidance updates?
A:Revenue guidance increased by $4 million at the midpoint, and EBITDA guidance increased by $7 million. Gross margins in Q4 are expected to be similar to Q2 due to seasonal promotions, and operating expenses are expected to rise by $2-3 million due to higher commissions and marketing spending. Devices remain under pressure but are showing improvement due to sales initiatives and pricing strategies.
Q:What is the company's approach to addressing higher churn rates?
A:Churn rates increased to 1.8% from 0.9% last year, primarily due to financial pressures on low-volume providers. The company is proactively reengaging these providers through improved support and training, aiming to bring churn rates back to historical levels over the next few quarters.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance for 2026, citing it as premature. They also did not provide detailed data on the financial impact of paused initiatives like the skincare line or specific timelines for achieving stabilization in device sales and churn rates.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Beauty Health
BeautyHealth job
BeautyHealth month
BeautyHealth opportunity
BeautyHealth side
BeautyHealth skin
Boosters booster
Cash activity
China consumables
Hydrafacial
cost control
demand planning
device platform
discipline cost
headcount
manufacturing
margin consumables
note
passion
phase
procedure
revenue decrease
segment revenue
shareholder value
spending
tariff exposure
technology
value device
volume
world
write offs
year
SKIN Transcript
SkinHealth Systems Inc. (SKIN) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call summary presents mixed signals: improved margins, reduced losses, and a strong cash position are positives, but declining revenues and device placements are concerning. The Q&A reveals cautious optimism about future growth and partnerships, but lacks concrete details. The guidance for 2026 suggests a challenging first half, with improvement expected later. Overall, the sentiment is balanced, leading to a neutral prediction for stock price movement over the next two weeks.
The Beauty Health Company (SKIN) Q4 2025 Earnings Call Transcript
Positive3-13
The company has raised its revenue and EBITDA guidance, indicating strong financial metrics. Despite a challenging macroeconomic environment, the focus on controllable growth levers and operational discipline is promising. The Q&A reveals improved churn rates and strategic targeting of new demographics, which could enhance market penetration. While there are some uncertainties, such as the lack of specifics on new products, the overall sentiment is positive, with innovative strategies in place for future growth.
The Beauty Health Company (SKIN) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call reveals positive developments: increased revenue and EBITDA guidance, successful price hikes, and promising product launches. Although device sales face challenges, consumables show growth, and stabilization efforts are underway. The company's focus on innovation and strategic pricing, coupled with a positive market response to price increases, indicates a potential stock price uplift. However, management's lack of specific guidance for 2026 and ongoing macroeconomic pressures temper expectations, suggesting a moderate positive sentiment.
The Beauty Health Company (SKIN) Q2 2025 Earnings Call Transcript
Unknown8-8
Despite exceeding Q1 revenue and EBITDA guidance, concerns about declining gross margins due to tariffs, increased R&D spending, and macroeconomic pressures, such as higher churn and ASP pressure, neutralize the positive impact. The optimistic guidance and strategic initiatives like new product launches and loyalty programs offer potential upside, but uncertainties in execution and financial health create a balanced outlook.
SKIN Slides
SKIN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
